Selecta Biosciences to Announce Date of First Quarter 2019 Financial Results Conference Call
May 02 2019 - 8:00AM
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a
clinical-stage biotechnology company focused on unlocking the full
potential of biologic therapies based on its immune tolerance
platform technology, ImmTOR (SVP Rapamycin), today announced that
it plans to issue its first quarter 2019 financial results before
the open of the U.S. financial markets on Thursday, May 09, 2019.
At 8:30 a.m. ET that day, Selecta will host a
conference call and live audio webcast to discuss first quarter
2019 financial results and provide a corporate update. Investors
and the public can access a live and archived webcast of this call
via the Investors & Media section of the company’s website,
http://selectabio.com. Individuals may also participate in the live
call via telephone by dialing (844) 845-4170 (domestic) or (412)
717-9621 (international) and may access a teleconference replay for
one week by dialing (877) 344-7529 (domestic) or (412) 317-0088
(international) and using confirmation code 10127202.
About Selecta Biosciences,
Inc.Selecta Biosciences, Inc. is a clinical-stage
biotechnology company focused on unlocking the full potential of
biologic therapies based on its immune tolerance technology
(ImmTOR) platform. Selecta plans to combine ImmTOR with a range of
biologic therapies for rare and serious diseases that require new
treatment options due to high immunogenicity. The company’s current
proprietary pipeline includes ImmTOR-powered therapeutic enzyme and
gene therapy product candidates. SEL-212, the company’s lead
product candidate, is being developed to treat chronic refractory
gout patients and resolve their debilitating symptoms, including
flares and gouty arthritis. Selecta’s proprietary gene therapy
product candidates are in preclinical development for certain rare
inborn errors of metabolism and incorporate ImmTOR with the goal of
addressing barriers to repeat administration. Selecta is based in
Watertown, Massachusetts. For more information, please visit
http://selectabio.com.
Forward-Looking StatementsThis
press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the timing of
future events. All such forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. Such risks and
uncertainties include but are not limited to those set forth in the
“Risk Factors” section of Selecta’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission, or SEC, on March
15, 2019, and in other filings that Selecta makes with the SEC. In
addition, any forward-looking statements included in this press
release represent Selecta’s views only as of the date of its
publication and should not be relied upon as representing its views
as of any subsequent date. Selecta specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Investors:
Sarah McCabeStern Investor Relations,
Inc.+1-212-362-1200sarah@sternir.com
Media:Lauren TortoreteSpectrum
Science Communications,
Inc.+1-212-468-5379ltortorete@spectrumscience.com
Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Selecta Biosciences (NASDAQ:SELB)
Historical Stock Chart
From Apr 2023 to Apr 2024